• Mashup Score: 0
    Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study - 8 month(s) ago

    In the single-arm, open-label, multicenter, phase 2 PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom hematopoietic stem cell transplantation (HSCT) was not intended resulted in high response rates, durable responses, and a safety profile consistent with previous reports. Here, we analyzed changes in health-related quality of life (HRQOL) in patients who received liso-cel in PILOT. Patients received liso-cel, an autologous, CD19-directed, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells, for a total target dose of 100 × 10⁶ CAR+ T cells. HRQOL, a secondary endpoint of PILOT, was assessed as prespecified using 3 patient-reported outcome instruments (EORTC QLQ-C30; FACT-LymS; EQ-5D-5L). Evaluable datasets for the EORTC QLQ-C30, FACT-LymS, EQ-5D-5L health utility index, and EQ-5D visual ana

    Source: haematologica.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of majorajay
      majorajay

      Mini-thread on patient-reported outcomes (PROs) from the phase II PILOT trial of second-line liso-cel in patients not eligible for ASCT, now published @Haematologica by Dr. @ligordon et al. #lymsm #tcellrx #celltherapy https://t.co/OWg3ZBciqH 1/ https://t.co/NyXJTeYBJt

  • Mashup Score: 2
    Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies - 9 month(s) ago

    Chimeric antigen receptor (CAR)-modified T cells have demonstrated remarkable efficacy in treating B-cell leukemia. However, treated patients may potentially develop side effects, such as cytokine release syndrome (CRS), the mechanisms of which remain unclear. Here, we collected 43 serum samples from eight patients with B-cell acute lymphoblastic leukemia (B-ALL) before and five time points after CD19-specific CAR-T cell treatment. Using TMTpro 16-plex-based quantitative proteomics, we quantified 1151 proteins and profiled the longitudinal proteomes analysis of each patient. Seven days after therapy, we found the most dysregulated inflammatory proteins. Lipid metabolism proteins, including APOA1, decreased after therapy, reached their minimum after 7 days, and then gradually recovered. Hence, APOA1 has been selected as a potential biomarker of the CRS disease progression. Furthermore, we identified CD163 as a potential biomarker of CRS severity. These two biomarkers were successfully v

    Source: pubs.acs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell https://t.co/BFxU4gAtC4 @CART_Therapy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy Interesting data APOA1 and CD163

  • Mashup Score: 0
    Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients - 9 month(s) ago

    Abstract. Purpose: Although CD19 CAR-T cell therapy has shown remarkable success in B cell malignancies, a substantial fraction of patients does not obtain a long-term clinical response. This could be influenced by the quality of the individual CAR-T infusion product. To shed some light on this, clinical outcome was correlated to characteristics of CAR-T cell infusion products. Patients and Methods: In this phase II study patients with B cell lymphoma (n=23) or leukemia (n=1) received one or two infusions of third generation CD19-directed CAR-T cells (2×108/m2). The clinical trial was registered at clinicaltrials.gov: NCT03068416. We investigated the transcriptional profile of individual third generation CD19 CAR-T infusion products using targeted single-cell RNA sequencing and multicolor flow cytometry. Results: Two CAR-T infusions were not better than one in the settings used in this study. As for the CAR-T infusion products we found that effector-like CD8+CAR-T cells with a high pol

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CARTTherapy
      CARTTherapy

      Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients https://t.co/clWgr5NSKI @CART_Therapy #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy

Load More